- Home
- PRG vs XERS Comparison
PRG vs XERS Comparison
Compare PRG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- XERS
- Stock Information
- Founded
- PRG 2020
- XERS 2005
- Country
- PRG United States
- XERS United States
- Employees
- PRG N/A
- XERS N/A
- Industry
- PRG Diversified Commercial Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- XERS Health Care
- Exchange
- PRG Nasdaq
- XERS Nasdaq
- Market Cap
- PRG 1.4B
- XERS 1.3B
- IPO Year
- PRG N/A
- XERS 2018
- Fundamental
- Price
- PRG $28.19
- XERS $9.92
- Analyst Decision
- PRG Hold
- XERS Strong Buy
- Analyst Count
- PRG 6
- XERS 7
- Target Price
- PRG $34.33
- XERS $9.43
- AVG Volume (30 Days)
- PRG 414.9K
- XERS 2.2M
- Earning Date
- PRG 10-22-2025
- XERS 11-06-2025
- Dividend Yield
- PRG 1.86%
- XERS N/A
- EPS Growth
- PRG 10.59
- XERS N/A
- EPS
- PRG 3.96
- XERS N/A
- Revenue
- PRG $2,507,179,000.00
- XERS $246,025,000.00
- Revenue This Year
- PRG $1.28
- XERS $43.89
- Revenue Next Year
- PRG $0.64
- XERS $20.40
- P/E Ratio
- PRG $7.07
- XERS N/A
- Revenue Growth
- PRG 3.71
- XERS 35.62
- 52 Week Low
- PRG $23.50
- XERS $2.82
- 52 Week High
- PRG $49.90
- XERS $10.03
- Technical
- Relative Strength Index (RSI)
- PRG 28.98
- XERS 73.60
- Support Level
- PRG $29.22
- XERS $9.48
- Resistance Level
- PRG $32.03
- XERS $10.02
- Average True Range (ATR)
- PRG 1.24
- XERS 0.37
- MACD
- PRG -0.29
- XERS 0.04
- Stochastic Oscillator
- PRG 7.72
- XERS 90.19
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).